展会邀请 | 德泰生物与您相约9.11-12 第三届生物偶联药全球创新峰会（Global XDC2024）

Keynote Speech

• Rina-S-the missing link(er) 

• Protein homeostasis by dual-precision targeted protein degradation and stabilization 

• A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs 

• MYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression

• NTX1105: development of a best-in-class ADC targeting Nectin-4 

• Collaborating within the global life science ecosystem to advance breakthrough science

论坛一：Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies

• Next generation ADCs: novel targets, payloads, linkers and conjugation technologies

• Nexatecan™: OHPAS-able Topo1 inhibitor for ADC

• Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker,   and dual payload system

• Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads

• CS5001, a potential best-in-class ROR1 ADC

• Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload

• Polysorbates in biopharmaceuticals-approaches to mitigate risk

论坛二：Bioconjugates development beyond ADCs

• RDC-the exploration of new drug modality in unmet clinical need

• Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?

• Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies

• Fully human common light chain technology for novel ADCs

论坛三：Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)

• Harnessing AbClick Pro^® for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index

• An overview on the new topoisomerases inhibitors technologies

• Next generation ADCs:novel targets, payloads, linkers and conjugation technologies

• Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)

论坛四：CMC challenges and commercialization strategies

• CMC scale-up challenges and COGs for site specific ADCs

• Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment

• The integrated analytical platform enables accelerated CMC development of XDCs

• QbD considerations for ADC process

• How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing

• Non-clinical strategies for ADC drugs

DETAIBIO